On October 4th, 2010, Enzo Biochem, Inc. (NYSE:ENZ) reported that, following filing of a investigational new drug (NYSE:IND) application with the FDA, its Enzo Therapeutics division is commencing a clinical trial of Optiquel™ , Enzo Biochem’s proprietary oral therapeutic for chronic non-infectious uveitis. The trial is designed as a randomized, double-masked, placebo-controlled study with a long-term follow-up and is being conducted by the National Institute of Health’s National Eye Institute (NASDAQ:NEI). Robert Nussenblatt, MD, Chief of NEI’s Laboratory of Immunology, will serve as Principal Investigator.
Optiquel™ has been awarded orphan drug status in the European Union and a similar designation may be applied for in the US. Enzo owns the exclusive rights to both US and international patents claiming the use of this compound for the treatment of uveitis. An investigator-initiated clinical trial of Optiquel™ in Germany demonstrated a therapeutic effect with no treatment-related side effects.
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community. Since Enzo Biochem’s founding in 1976, Enzo Biochem’s strategic focus has been on the development of enabling technologies in the life sciences field.
Douglas Lake Minerals Inc. (OTCBB:DLKM) is pleased to provide an update regarding its recently acquired Handeni Project which is located in the rapidly developing region of eastern Tanzania. Douglas Lake Minerals’ 100% owned Handeni Project consists of four prospecting licenses covering approximately 800 km(2) which are directly adjacent to, and partly surround, Canaco Resources Inc’s (V.CAN) 200 km(2) Kilindi license which holds the Magambazi gold mineralization occurrence.
Douglas Lake Minerals is pleased to provide the results of the recent exploration program conducted on PLR PLR4973/2008, subsequently subdivided into four PL’s (PL6742/2010, PL6743/2010, PL6744/2010 and PL6779/2010), based on the outcomes of the first phase of the continuous exploration program conducted since 2008. This exploration phase included a fixed-wing aircraft flown aeromagnetic and radiometric survey at a line spacing of 200m and a height of 80m, subsequent interpretation of data and ground follow-up. The survey and interpretation was conducted according to internationally accepted standards by the Council for Geoscience, South Africa.
Douglas Lake Minerals is an emerging mineral exploration company focused on exploring mining opportunities in Tanzania.
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced that the first patient has been dosed in a Phase I, single arm, dose escalation study at the Indiana University Cancer Center of intravenous (IV) palifosfamide (ZIO-201) in combination with etoposide (VP-16) and cisplatin/carboplatin (platinum) in the treatment of small cell lung cancer (SCLC) and other cancers. The Phase I study is expected to enroll 12 to 15 patients and will assess the safety of the palifosfamide/etoposide/platinum regimen for the planned randomized Phase II study in SCLC patients with extensive disease where the etoposide/platinum combination is standard of care.
ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of a portfolio of cancer drugs in North America.
ADDvantage Technologies Group Inc. (Nasdaq:AEY) announced that its subsidiary, Tulsat, has entered into a new system integrator/reseller agreement with Cisco, which will enable Tulsat to sell both IT and Service Provider Video Technology Group (”SPVTG”) related products in the United States. This agreement replaces its prior distributor agreement with Cisco, which expired December 20, 2010. Under the terms of the new agreement, Tulsat will purchase the majority of its new Cisco product inventory through a primary stocking distributor as opposed to purchasing directly from Cisco as it did under the prior agreement.
ADDvantage Technologies Group, Inc., through its subsidiaries, distributes cable television equipment and hardware to the cable television industry in North America, Central America, and South America.
EnteroMedics, Inc. (Nasdaq:ETRM) announced the closing of its previously announced public offering of 17.02 million shares of the Company’s common stock together with warrants to purchase an additional 17.02 million shares of common stock, which includes 2.22 million shares of common stock and corresponding warrants pursuant to the exercise in full by the underwriter of its over-allotment option, at an aggregate price of $1.75 per share and corresponding warrant. Total net proceeds to the Company from the offering are approximately $27.6 million after deducting underwriting discounts and commissions and estimated offering expenses.
EnteroMedics Inc., a development stage medical device company, focuses on design and development of devices that use neuroblocking technology to treat obesity and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.